Moderna

Moderna (NASDAQ-GS: MRNA) is a biotechnological and pharmaceutical company headquartered in Cambridge, Massachusetts. It was established in 2010 and was listed on Nasdaq in 2018. Moderna primarily engages in the development and clinical testing of novel mRNA-based therapy for a diverse array of illnesses, such as infectious diseases, immuno-oncology, rare diseases, cardiac diseases, and autoimmune diseases. In FY2023, the company's total revenue reached USD 6.8 billion.

Moderna is better known for its Covid-19 vaccine, SPIKEVAX, which was developed in 2020 and received FDA approval in 2022. Moderna’s other major milestones include initiating the first in-human dose of mRNA-1440 (a candidate vaccine for the H10N8 flu) and the first in-human dosing for mRNA-1653 (a combination vaccine) in 2015, along with the dosing of the first antibody encoded by mRNA in a clinical trial in 2019. 

Moderna generates revenue through three segments: Product Sales, Grants, and Collaborations. Product Sales is the largest segment, which primarily includes the sale of its Covid-19 vaccine. In FY 2023, Moderna’s total revenue amounted to USD 6.8 billion, accounting for a decrease of 184% YoY due to low vaccination rates. By geography, US was its largest market, accounting for 28% of total revenue in FY2023, followed by Europe (20%).